… We assumed that gefitinib and erlotinib in the experimental … in this meta-analysis of gefitinib
and erlotinib as most of the … significantly differ between gefitinib or erlotinib vs chemotherapy …

… Overall survival after start of TK inhibitors in patients … overall survival both in univariate
analysis and in multivariate analysis. Gefitinib and erlotinib did not lead to different overall survival …

8072 Background: We performed an individual pts data meta-analysis using trials that
compared G or E vs platinum doublet chemotherapy (CT) on OS outcome. Methods: Treatment-…

… -line erlotinib or gefitinib in EGFR mutation-positive advanced NSCLC and have demonstrated
significantly longer progression-free survival (… The gefitinib trials are completed and none …

… Compared with standard chemotherapy, erlotinib conferred a significant progression-free
survival benefit in patients with advanced EGFR mutation-positive NSCLC and was associated …

… Korea directly compared gefitinib with erlotinib for the second… results on progression-free
survival, overall survival, overall … with direct comparison of gefitinib with erlotinib that had been …

… maintenance of pemetrexed significantly improved the overall survival (OS) in advanced …
of progression-free survival (PFS) and overall survival (OS) with maintenance erlotinib …

… Eligible patients were randomised to receive erlotinib (150 mg per day) or gefitinib (250 …
erlotinib is superior to gefitinib in efficacy. The primary end point was progression-free survival…

… With 13.2 months of follow-up, the median overall survival (OS) for the total 342 patients …
median progression-free survival (PFS) was 3.2 months (95% CI, 2.65-3.75 months). The overall …

… Median overall survival was 6.7 and 4.7 months for erlotinib … evidence with erlotinib and
gefitinib indicates gefitinib's activity … patients with NSCLC is at least as good as that of erlotinib. …